2022
DOI: 10.1002/14651858.cd015023.pub2
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological interventions for pain and sedation management in newborn infants undergoing therapeutic hypothermia

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 10 publications
(7 citation statements)
references
References 81 publications
0
7
0
Order By: Relevance
“…Limited dosing information is currently available on drugs that are commonly administered to HIE neonates receiving TH [ 37 , 38 , 39 , 40 ]. Because of alterations in drug PKs, this vulnerable population requires unique clinical pharmacologic considerations [ 15 , 16 , 17 , 18 , 19 ].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Limited dosing information is currently available on drugs that are commonly administered to HIE neonates receiving TH [ 37 , 38 , 39 , 40 ]. Because of alterations in drug PKs, this vulnerable population requires unique clinical pharmacologic considerations [ 15 , 16 , 17 , 18 , 19 ].…”
Section: Discussionmentioning
confidence: 99%
“…Because of alterations in drug PKs, this vulnerable population requires unique clinical pharmacologic considerations [ 15 , 16 , 17 , 18 , 19 ]. HIE infants treated with TH require SA to improve both discomfort and pain from cooling, intubation, and mechanical ventilation [ 39 , 40 , 41 , 42 , 43 ]. To date, there are no standardized dosing guidelines for SA during TH [ 40 , 41 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…We could not find other systematic reviews addressing the topic of our study. The protocol of a Cochrane review has been published, however it will include only randomized trials and a narrower list of drugs [35].…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, it was found to decrease the time to extubation as well as the duration of mechanical ventilation [139]. It is worth noting that during the last several years, dexmedetomidine has attracted the interest of neonatologists as an analgesic/sedative agent in neonates undergoing therapeutic hypothermia due to its possible neuroprotective action [140,141] However, so far, there are insufficient data from randomized clinical trials evaluating the use of any analgesic-sedative agent during therapeutic hypothermia, including clonidine and dexmedetomidine [142]. Dexmedetomidine has been used in neonates at a starting dose of 0.2 to 0.3 mcg/kg/h, escalating in 0.1 mcg/kg/h increments depending on pain / sedation assessment scores, up to a median maximum dose of 0.5 mcg/kg/h (Table 3) [143].…”
Section: Alpha-2 Agonistsmentioning
confidence: 99%